1. Pakzad R, Rafiemanesh H, Ghoncheh M, Sarmad A, Salehiniya H, Hosseini S, et al. Prostate Cancer in Iran: Trends in Incidence and Morphological and Epidemiological Characteristics. Asian Pac J Cancer Prev 2016;17:839-43. [DOI:10.7314/APJCP.2016.17.2.839]

2. Bidgoli SA, Jabari N, Zavarhei MD. Prostate-specific antigen levels in relation to background factors: are there links to endocrine disrupting chemicals and AhR expression? Asian Pac J Cancer Prev 2014;15:6121-5. [DOI:10.7314/APJCP.2014.15.15.6121]

3. Ha Chung B, Horie S, Chiong E. The incidence, mortality and risk factors of prostate cancer in Asian men. Prostate Int 2019 ;7:1-8. [DOI:10.1016/j.prnil.2018.11.001]

4. Hassanipour S, Fathalipour M, Salehiniya H. The incidence of prostate cancer in Iran: a systematic review and meta-analysis. Prostate Int 2018;6:41-45. [DOI:10.1016/j.prnil.2017.11.003]

5. Perdana NR, Mochtar CA, Umbas R, Hamid AR. The Risk Factors of Prostate Cancer and Its Prevention: A Literature Review. Acta Med Indones 2016; 48: 228-238.

6. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The Epidemiology of Prostate Cancer. Cold Spring Harb Perspect Med 2018;8:030361. [DOI:10.1101/cshperspect.a030361]

7. Perez-Cornago A, Key TJ, Allen NE, Fensom GK, Bradbury KE, Martin RM, et al. Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study. Br J Cancer 2017;1710:1562-1571. [DOI:10.1038/bjc.2017.312]

8. Peisch SF, Van Blarigan EL, Chan JM, Stampfer MJ, Kenfield SA. Prostate cancer progression and mortality: a review of diet and lifestyle factors. World J Urol 2017; 35:867-874. [DOI:10.1007/s00345-016-1914-3]

9. Ha Chung B, Horie S, Chiong E. The incidence, mortality, and risk factors of prostate cancer in Asian men. Prostate Int. 2019;7:1-8. [DOI:10.1016/j.prnil.2018.11.001]

10. Eton DT, Lepore SJ.Prostate cancer and health & related quality of life: a review of the literature. Psycho-Oncology J 2002; 11: 307-26. [DOI:10.1002/pon.572]

11. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J; National Prostate Cancer Register (NPCR) of Sweden. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 2010; 102:950-8. [DOI:10.1093/jnci/djq154]

12. Adamowicz K. Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials. Qual Life Res 2017; 26: 813-822. [DOI:10.1007/s11136-016-1429-9]

13. Harrington CB, Hansen JA, Moskowitz M, Todd BL, Feuerstein M.IT'S not over when it's over: long-term symptoms in cancer survivors- a systematic review. Int J Psychiatr Med 2010;40: 163-81. [DOI:10.2190/PM.40.2.c]

14. Levine, Benjamin A. Sherer and Laurence A. Current management of erectile dysfunction in prostate cancer survivors. Curr Opin Urol 2014;24: 401-6. [DOI:10.1097/MOU.0000000000000072]

15. Helgason AR, Adolfsson J, Dickman P, Fredrikson M, Arver S, Steineck G. Waning sexual function-the most important disease-specific distress for patients with prostate cancer. Br J Cancer 1996;73:1417-21. [DOI:10.1038/bjc.1996.268]

16. Sherer BA, Levine LA. Current management of erectile dysfunction in prostate cancer survivors. Curr Opin Urol 2014;24:401-6. [DOI:10.1097/MOU.0000000000000072]

17. Bella AJ, Shamloul R. Traditional Plant Aphrodisiacs and Male Sexual Dysfunction. Phytotherapy Research 2014; 28: 831-5. [DOI:10.1002/ptr.5074]

18. Penson DF. The effect of erectile dysfunction on quality of life following treatment for localized prostate cancer. Rev Urol 2001;3:113.

19. Neijenhuijs KI, Holtmaat K, Aaronson NK, Holzner B, Terwee CB, Cuijpers P, et al. The International Index of Erectile Function (IIEF)-A Systematic Review of Measurement Properties. J Sex Med 2019;16:1078-1091. [DOI:10.1016/j.jsxm.2019.04.010]

20. Serefoglu EC, Yaman O, Cayan S, Asci R, Orhan I, Usta MF, et al. The comparison of premature ejaculation assessment questionnaires and their sensitivity for the four premature ejaculation syndromes: results from the Turkish society of andrology sexual health survey. J Sex Med 2011;8:1177-85. [DOI:10.1111/j.1743-6109.2010.02183.x]

21. Lee N, Lee SH, Yoo HR, Yoo HS. Anti-fatigue effects of enzyme-modified ginseng extract: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med 2016;22:859-864. [DOI:10.1089/acm.2016.0057]

22. Adamowicz K. Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials. Qual Life Res 2017;26:813-822. [DOI:10.1007/s11136-016-1429-9]

23. Koike H, Kohjimoto Y, Iba A, Kikkawa K, Yamashita S, Iguchi T, et al. Hara I Health-related quality of life after robot-assisted radical prostatectomy compared with laparoscopic radical prostatectomy. J Robot Surg 2017;11:325-331. [DOI:10.1007/s11701-016-0659-8]

24. Orakwe DE, Tijani KH, Jeje EA, Ogunjimi MA, Rufus WO, Alabi TO. Bilateral subcapsular orchiectomy versus bilateral total orchiectomy: Comparison of the quality of life post-orchiectomy. Niger Postgrad Med J 2018;25:43-47. [DOI:10.4103/npmj.npmj_169_17]

25. Ervandian M, Høyer M, Petersen SE, Sengeløv L, Hansen S, Kempel MM, et al. Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer. Scand J Urol 2017; 51:457-463. [DOI:10.1080/21681805.2017.1354314]

26. Gaither TW, Awad MA, Osterberg EC, Murphy GP, Allen IE, Chang A, et al. The Natural History of Erectile Dysfunction After Prostatic Radiotherapy: A Systematic Review and Meta-Analysis. J Sex Med 2017; 14:1071-1078. [DOI:10.1016/j.jsxm.2017.07.010]

27. D'Avino V, Palma G, Liuzzi R, Conson M, Doria F, Salvatore M, et al. Prediction of gastrointestinal toxicity after external beam radiotherapy for localized prostate cancer. Radiat Oncol 2015;8:80. [DOI:10.1186/s13014-015-0389-5]

28. Penson DF, Litwin MS.Quality of life after treatment for prostate cancer. Current Prostate Reports 2003;1: 55-65. [DOI:10.1007/s11918-003-0009-y]

29. Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016;375:1425-1437. [DOI:10.1056/NEJMoa1606221]

30. Rebillard X, Soulié M, Chartier Kastler E, Davin JL, Mignard JP, Moreau JL, et al. Association Francaise d'Urologie. High‐intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int 2008;101:1205-13. [DOI:10.1111/j.1464-410X.2008.07504.x]

31. Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int 2012;109:1648-54. [DOI:10.1111/j.1464-410X.2011.10578.x]

32. Liu JM, Yu CP, Chuang HC, Wu CT, Hsu RJ. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Autoimmune Diseases. Prostate Cancer Prostatic Dis 2019;22:475-482. [DOI:10.1038/s41391-019-0130-9]

33. Cancer.Net Editorial Board. Prostate Cancer: Types of Treatment. Available from: https://www.cancer.net/cancer-types/prostate-cancer/types-treatment.

34. Baker J, Ajani J, Scotté F, Winther D, Martin M, Aapro MS, et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009;13:49-59. [DOI:10.1016/j.ejon.2008.10.003]

35. Cui Y, Shu XO, Gao YT, Cai H, Tao MH, Zheng W. Association of Ginseng Use with Survival and Quality of Life among Breast Cancer Patients. Am J Epidemiol 2006;163:645-53. [DOI:10.1093/aje/kwj087]

36. AScholey A, Ossoukhova A, Owen L, Ibarra A, Pipingas A, He K, et al .Effects of American ginseng (Panax quinquefolius) on neurocognitive function: an acute, randomised, double-blind, placebo-controlled. Psychopharmacology (Berl) 2010; 212:345-56. [DOI:10.1007/s00213-010-1964-y]

37. ourmohamadi K, Ahmadzadeh A, Latifi M. Investigating the Effects of Oral Ginseng on the Cancer-Related Fatigue and Quality of Life in Patients with Non-Metastatic Cancer. Int J Hematol Oncol Stem Cell Res 2018;12;313-317. [DOI:10.18502/ijhoscr.v12i4.110]

38. Kim JH, Park CY, Lee SJ. Effects of Sun Ginseng on subjective quality of life in cancer patients: a double-blind, placebo-controlled pilot trial. J Clin Pharm Ther 2006;31:331-4. [DOI:10.1111/j.1365-2710.2006.00740.x]

39. Kim HS, Kim MK, Lee M, Kwon BS, Suh DH, Song YS. Effect of Red Ginseng on Genotoxicity and Health-Related Quality of Life after Adjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer: A Randomized, Double Blind, Placebo-Controlled Trial. Nutrients 2017;9:772. [DOI:10.3390/nu9070772]

40. Zhong Y, Wang XQ, Liu H, Liu J, hou W, Lin H S. A multicenter, large-sample, randomized clinical trial on improving the median survival time of advanced non-small cell lung cancer by combination of Ginseng Rg3 and chemotherapy. Zhonghua Zhong Liu Za Zhi 2018;40:295-299.

41. Daugherty M, Chelluri R, Bratslavsky G, Byler T. Are we underestimating the rates of incontinence after prostate cancer treatment? Results from NHANES. Int Urol Nephrol 2017;49:1715-1721. [DOI:10.1007/s11255-017-1660-5]

42. Sherer BA, Levine LA. Current management of erectile dysfunction in prostate cancer survivors. Curr Opin Urol 2014;24:401-6. [DOI:10.1097/MOU.0000000000000072]

43. Yun TK, Zheng S, Choi SY, Cai SR, Lee YS, Liu XY, et al. Non-organ-specific preventive effect of long-term administration of Korean red ginseng extract on incidence of human cancers. J Med Food 2010;13:489-94. [DOI:10.1089/jmf.2009.1275]

44. Nanao-Hamai M, Son BK, Komuro A, Asari Y, Hashizume T, Takayama KI, et al. Ginsenoside Rb1 inhibits vascular calcification as a selective androgen receptor modulator. Eur J Pharmacol 2019;859:172546. [DOI:10.1016/j.ejphar.2019.172546]

45. Borrelli F, Colalto C, Delfino DV, Iriti M, Izzo AA. Herbal Dietary Supplements for Erectile Dysfunction: A Systematic Review and Meta-Analysis. Drugs 2018;78:643-673. [DOI:10.1007/s40265-018-0897-3]

46. Choi YD, Park CW, Jang J, Kim SH, Jeon HY, Kim WG, et al. Effects of Korean ginseng berry extract on sexual function in men with erectile dysfunction: a multicenter, placebo-controlled, double-blind clinical study. 2 Int J Impot Res 2013;25:45-50. [DOI:10.1038/ijir.2012.45]

47. Tamler R, Mechanick JI. Dietary supplements and nutraceuticals in the management of andrologic disorders. Endocrinol Metab Clin North Am 2007; 36:533-52. [DOI:10.1016/j.ecl.2007.03.005]

48. Lee JK, Tan RB, Chung E. Erectile dysfunction treatment and traditional medicine-can East and West medicine coexist? Transl Androl Urol 2017;6:91-100. [DOI:10.21037/tau.2016.11.13]

49. Kim SK, GyuKo I, Park HJ, Chung JH, Cho KB, Kwon OY, et al. Effects of Panax ginseng on the nerve growth factor expression in testosterone induced benign prostatic hyperplasia. Saudi J Biol Sci 2018;25:66-70. [DOI:10.1016/j.sjbs.2016.07.005]

50. Kim SK, Chung JH, Lee BC, Lee SW, Lee KH, Kim YO. Influence of Panax ginseng on Alpha-Adrenergic Receptor of Benign Prostatic Hyperplasia. Int Neurourol J 2014; 18: 179-86. [DOI:10.5213/inj.2014.18.4.179]

51. Choi HK, Seong DH, Rha K. Clinical efficacy of Korean red ginseng for erectile dysfunction. Int J Impot Res 1995;7:181-6.

52. Choi YD, Park CW, Jang J, Kim SH, Jeon HY, Kim WG, et al. Effects of Korean ginseng berry extract on sexual function in men with erectile dysfunction: a multicenter, placebo-controlled, double-blind clinical study. Int J Impot Res 2013;25:45-50. [DOI:10.1038/ijir.2012.45]

53. Kim TH, Jeon SH, Hahn EJ, Paek KY, Park JK, Youn NY, et al. Effects of tissue-cultured mountain ginseng (Panax ginseng CA Meyer) extract on male patients with erectile dysfunction. Asian J Androl 2009;11:356-61. [DOI:10.1038/aja.2008.32]

54. De Andrade E, De Mesquita AA, de Almeida Claro J, De Andrade PM, Ortiz V, Paranhos M, et al. Study of the efficacy of Korean Red Ginseng in the treatment of erectile dysfunction. Asian J Androl 2007;9:241-4 [DOI:10.1111/j.1745-7262.2007.00210.x]

55. Hong B, Ji YH, Hong JH, Nam KY, Ahn TY.A double-blind crossover study evaluating the efficacy of Korean red ginseng in patients with erectile dysfunction: a preliminary report. J Urol 2002;168:2070-3. [DOI:10.1016/S0022-5347(05)64298-X]

56. Yennurajalingam S, Reddy A, Tannir NM, Chisholm GB, Lee RT, Lopez G, et al. High-Dose Asian Ginseng (Panax Ginseng) for Cancer-Related Fatigue: A Preliminary Report.Integr Cancer Ther 2015;14:419-27. [DOI:10.1177/1534735415580676]

57. Yennurajalingam S, Tannir NM, Williams JL, Lu Z, Hess KR, Frisbee-Hume S, et al. A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients with Advanced Cancer. J Natl Compr Canc Netw 2017;15:1111-1120. [DOI:10.6004/jnccn.2017.0149]

58. Barton DL, Liu H, Dakhil SR, Linquist B, Sloan JA, Nichols CR, et al. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related Fatigue: A randomized, Double-Blind trial, N07c2. J Natl Cancer Inst 2013 ;105:1230-8. [DOI:10.1093/jnci/djt181]

59. Barton DL, Soori GS, Bauer BA, Sloan JA, Johnson PA, Figueras C, et al. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer 2010;18:179-87. [DOI:10.1007/s00520-009-0642-2]

60. Lee N, Lee SH, Yoo HR, Yoo HS. Anti-fatigue effects of enzyme-modified ginseng extract: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med 2016;22:859-864. [DOI:10.1089/acm.2016.0057]

61. Kim SM, Lee SY, Cho JS, Son SM, Choi SS, Yun YP, et al. Combination of Ginsenoside Rg3 With Docetaxel Enhances the Susceptibility of Prostate Cancer Cells via Inhibition of NF-kappaB. Eur J Pharmacol 2010;631:1-9. [DOI:10.1016/j.ejphar.2009.12.018]

62. Chen S, Wang Z, HuangY, O'Barr S A., Wong R A., YeungS,et al. Ginseng and anticancer drug combination to improve cancer chemotherapy: a critical review. Evid Based Complement Alternat Med 2014;2014:168940. [DOI:10.1155/2014/168940]

63. YUNa, TAIK-KOO. Asian Studies on Cancer Chemoprevention. Ann N Y Acad Sci 1999;889:157-92. [DOI:10.1111/j.1749-6632.1999.tb08734.x]

64. Wong AS, Che CM, Leung KW. Recent advances in ginseng as cancer therapeutics: a functional and mechanistic overview. Nat Prod Rep 2015; 32:256-72. [DOI:10.1039/C4NP00080C]

65. Kim JH, Park CY, Lee SJ. Effects of Sun Ginseng on Subjective Quality of Life in Cancer Patients: A Double-Blind, Placebo-Controlled Pilot Trial. J Clin Pharm Ther 2006;31:331-4. [DOI:10.1111/j.1365-2710.2006.00740.x]

66. Khera M, Goldstein I. Erectile dysfunction. BMJ Clin Evid 2011;2011:1803.

67. Figueiredo J C , Grau M V, Haile R W, Sandler RS, Summers RW, Bresalier RS, et al. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst 2009;101:432-5. [DOI:10.1093/jnci/djp019]